Gate Neurosciences Doses First Subject in a Translational EEG Biomarker Study of Apimostinel, a Rapid-Acting Treatment for Acute Depressive Disorders - Business Wire

Submitted by Anonymous (not verified) on Tue, 11/29/2022 - 13:01

Gate Neurosciences Doses First Subject in a Translational EEG Biomarker Study of Apimostinel, a Rapid-Acting Treatment for Acute Depressive Disorders Business Wire

Log in to post comments